Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253147 · ClinicalTrials.gov registry record · NA
TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds
A NA study of Nasolabial Folds, Wrinkles, sponsored by Teoxane.
- Completed
- Registry status
- NA
- Development phase
- 140
- Enrollment target
- 4
- Study locations
NCT02253147 is a NA study of Nasolabial Folds, Wrinkles that has completed, run by Teoxane. The registered enrollment target is 140 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT02253147, a NA study of Nasolabial Folds, Wrinkles, has completed, sponsored by Teoxane.
- COMPLETED
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness and safety of TEOSYAL® RHA Ultra Deep versus Perlane-L® in the treatment of moderate to severe nasolabial folds. This is a controlled, randomized, double-blinded, within subject (split-face), multicenter, prospective clinical study.
Conditions Studied
Interventions
- DEVICE TEOSYAL® RHA Ultra Deep
Study Locations (4)
California
- United States - Beverly Hills
Florida
- United States - Bradenton
North Carolina
- United States - Chapel Hill
Pennsylvania
- United States - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253147
The ClinicalTrials.gov registry entry for NCT02253147 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teoxane, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nasolabial Folds, Wrinkles appearing as the primary indexed condition, and to 1 intervention - of which TEOSYAL® RHA Ultra Deep is the first listed.
NCT02253147 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02253147 about?
NCT02253147 is a clinical study titled "TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds". The purpose of this study is to compare the effectiveness and safety of TEOSYAL® RHA Ultra Deep versus Perlane-L® in the treatment of moderate to severe nasolabial folds. This is a controlled, randomized, double-blinded, within subject (split-face), multicenter, prospective clinical study.
What is the current status of trial NCT02253147?
This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2014-09. Estimated completion is 2016-05.
What conditions does trial NCT02253147 study?
This clinical trial studies the following conditions: Nasolabial Folds, Wrinkles.
What interventions are being tested in trial NCT02253147?
The interventions under investigation include: TEOSYAL® RHA Ultra Deep (DEVICE).
Who is sponsoring clinical trial NCT02253147?
This trial is sponsored by Teoxane, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02253147 being conducted?
This trial has 4 study locations across California, Florida, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.